BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31894347)

  • 1. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
    Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
    Singleton WGB; Bienemann AS; Woolley M; Johnson D; Lewis O; Wyatt MJ; Damment SJP; Boulter LJ; Killick-Cole CL; Asby DJ; Gill SS
    J Neurosurg Pediatr; 2018 Sep; 22(3):288-296. PubMed ID: 29856296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
    Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.
    Gibson EG; Campagne O; Selvo NS; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1009-1020. PubMed ID: 34586478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin and [Pt(R,R-DACH)(panobinostat
    Boulet MHC; Marsh LK; Howarth A; Woolman A; Farrer NJ
    Dalton Trans; 2020 May; 49(17):5703-5710. PubMed ID: 32297619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
    Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
    Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
    Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
    League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE
    J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK2 inhibitors display beneficial effects in preclinical models of
    Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
    Commun Biol; 2019; 2():156. PubMed ID: 31098401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
    Hollingworth MA; Zacharoulis S
    J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.
    Mueller S; Kline C; Stoller S; Lundy S; Christopher L; Reddy AT; Banerjee A; Cooney TM; Raber S; Hoffman C; Luks T; Wembacher-Schroeder E; Lummel N; Zhang Y; Bonner ER; Nazarian J; Molinaro AM; Prados M; Villanueva-Meyer JE; Gupta N
    Neuro Oncol; 2023 Nov; 25(11):2074-2086. PubMed ID: 37318058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model.
    Homan MJ; Franson A; Ravi K; Roberts H; Pai MP; Liu C; He M; Matvekas A; Koschmann C; Marini BL
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):555-562. PubMed ID: 34115161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
    Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
    Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery.
    Tosi U; Kommidi H; Bellat V; Marnell CS; Guo H; Adeuyan O; Schweitzer ME; Chen N; Su T; Zhang G; Maachani UB; Pisapia DJ; Law B; Souweidane MM; Ting R
    ACS Chem Neurosci; 2019 May; 10(5):2287-2298. PubMed ID: 30838861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
    Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
    PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.